Travere therapeutics and csl vifor announce ema has accepted for review the conditional marketing authorization application for sparsentan for the treatment of iga nephropathy

A review decision by the european medicines agency (ema) is expected in the second half of 2023
TVTX Ratings Summary
TVTX Quant Ranking